Article Versions Notes

Grünwald V, Rußwurm K, Eckert R, Seseke S, Standhaft D, Hegemann M, Baumann S, Brenneis H, Seidel M, Rau O, et al. First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex. Cancers. 2025; 17(24):3910. https://doi.org/10.3390/cancers17243910

Grünwald, Viktor, Karen Rußwurm, Ralf Eckert, Sandra Seseke, Diana Standhaft, Miriam Hegemann, Steffen Baumann, Horst Brenneis, Michael Seidel, Olrik Rau, and et al. 2025. "First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex" Cancers 17, no. 24: 3910. https://doi.org/10.3390/cancers17243910

Grünwald, V., Rußwurm, K., Eckert, R., Seseke, S., Standhaft, D., Hegemann, M., Baumann, S., Brenneis, H., Seidel, M., Rau, O., Schirrmacher-Memmel, S., Hellmis, E., Fieseler, C. F., Doehn, C., Ziske, C., Distelrath, A., Marschner, N., Ivanyi, P., Herold, M., ... Bögemann, M. (2025). First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex. Cancers, 17(24), 3910. https://doi.org/10.3390/cancers17243910